心力衰竭临床试验的惊人愚蠢：关于研究者和指南如何权衡证据的不便真相。 - Suppr

Suppr

超能文献

Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.

作者信息

Packer Milton

机构信息

From the Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.

出版信息

Circ Heart Fail. 2016 Apr;9(4):e002837. doi: 10.1161/CIRCHEARTFAILURE.116.002837.

DOI:10.1161/CIRCHEARTFAILURE.116.002837

PMID:27009552

Abstract

摘要

相似文献

Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.

Circ Heart Fail. 2016 Apr;9(4):e002837. doi: 10.1161/CIRCHEARTFAILURE.116.002837.

Heart failure: Heart failure clinical trials: how do we define success?

Nat Rev Cardiol. 2013 Sep;10(9):492-4. doi: 10.1038/nrcardio.2013.115. Epub 2013 Aug 6.

Beyond effect size: consideration of the minimum effect size of interest in anesthesia trials.

Anesth Analg. 2012 Feb;114(2):471-5. doi: 10.1213/ANE.0b013e31823d2ab7.

N-of-1 trials in oncology.

Lancet Oncol. 2015 Aug;16(8):885-6. doi: 10.1016/S1470-2045(15)00062-5.

The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.

Circulation. 2004 Jun 1;109(21):e305-7. doi: 10.1161/01.CIR.0000129020.43304.A7.

Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.

Circ Heart Fail. 2016 Sep;9(9). doi: 10.1161/CIRCHEARTFAILURE.115.002528.

How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?

Annu Rev Pharmacol Toxicol. 2015;55:169-89. doi: 10.1146/annurev-pharmtox-010814-124614. Epub 2014 Aug 21.

Note on special technical issue on adaptive designs for clinical trials.

J Biopharm Stat. 2012;22(4):615-6. doi: 10.1080/10543406.2012.684507.

Analyzing and Interpreting Clinical Trials.

Gastroenterology. 2016 Apr;150(4):797-800. doi: 10.1053/j.gastro.2016.02.065. Epub 2016 Feb 26.

Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):594-600. doi: 10.1161/CIRCOUTCOMES.112.966150.

引用本文的文献

3-Hydroxyflavone is a mildly active and safe cobalt chelator while cobalt markedly enhances baicalein toxicity toward erythrocytes.

RSC Adv. 2023 Oct 5;13(42):29242-29251. doi: 10.1039/d3ra02735j. eCollection 2023 Oct 4.

A Change of Heart: Human Cardiac Tissue Engineering as a Platform for Drug Development.

Curr Cardiol Rep. 2022 May;24(5):473-486. doi: 10.1007/s11886-022-01668-7. Epub 2022 Mar 5.

Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.

J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):39-50. doi: 10.1007/s10928-021-09785-6. Epub 2021 Oct 12.

Transforming the interpretation of significance in heart failure trials.

Eur J Heart Fail. 2020 Feb;22(2):177-180. doi: 10.1002/ejhf.1668. Epub 2019 Nov 14.

Tailoring therapy for ischemic cardiomyopathy: is Laplace's law enough?

Ther Adv Cardiovasc Dis. 2017 Sep;11(9):231-234. doi: 10.1177/1753944717718719. Epub 2017 Jul 10.

Branko Furst's Radical Alternative: Is the Heart Moved by the Blood, Rather Than Vice Versa?

P T. 2017 Jan;42(1):33-39.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.

作者信息

Packer Milton

机构信息

From the Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.

出版信息

Circ Heart Fail. 2016 Apr;9(4):e002837. doi: 10.1161/CIRCHEARTFAILURE.116.002837.

DOI:10.1161/CIRCHEARTFAILURE.116.002837

PMID:27009552

Abstract

摘要

相似文献

Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.

Circ Heart Fail. 2016 Apr;9(4):e002837. doi: 10.1161/CIRCHEARTFAILURE.116.002837.

Heart failure: Heart failure clinical trials: how do we define success?

Nat Rev Cardiol. 2013 Sep;10(9):492-4. doi: 10.1038/nrcardio.2013.115. Epub 2013 Aug 6.

Beyond effect size: consideration of the minimum effect size of interest in anesthesia trials.

Anesth Analg. 2012 Feb;114(2):471-5. doi: 10.1213/ANE.0b013e31823d2ab7.

N-of-1 trials in oncology.

Lancet Oncol. 2015 Aug;16(8):885-6. doi: 10.1016/S1470-2045(15)00062-5.

The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.

Circulation. 2004 Jun 1;109(21):e305-7. doi: 10.1161/01.CIR.0000129020.43304.A7.

Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.

Circ Heart Fail. 2016 Sep;9(9). doi: 10.1161/CIRCHEARTFAILURE.115.002528.

How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?

Annu Rev Pharmacol Toxicol. 2015;55:169-89. doi: 10.1146/annurev-pharmtox-010814-124614. Epub 2014 Aug 21.

Note on special technical issue on adaptive designs for clinical trials.

J Biopharm Stat. 2012;22(4):615-6. doi: 10.1080/10543406.2012.684507.

Analyzing and Interpreting Clinical Trials.

Gastroenterology. 2016 Apr;150(4):797-800. doi: 10.1053/j.gastro.2016.02.065. Epub 2016 Feb 26.

Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):594-600. doi: 10.1161/CIRCOUTCOMES.112.966150.

引用本文的文献

3-Hydroxyflavone is a mildly active and safe cobalt chelator while cobalt markedly enhances baicalein toxicity toward erythrocytes.

RSC Adv. 2023 Oct 5;13(42):29242-29251. doi: 10.1039/d3ra02735j. eCollection 2023 Oct 4.

A Change of Heart: Human Cardiac Tissue Engineering as a Platform for Drug Development.

Curr Cardiol Rep. 2022 May;24(5):473-486. doi: 10.1007/s11886-022-01668-7. Epub 2022 Mar 5.

Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.

J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):39-50. doi: 10.1007/s10928-021-09785-6. Epub 2021 Oct 12.

Transforming the interpretation of significance in heart failure trials.

Eur J Heart Fail. 2020 Feb;22(2):177-180. doi: 10.1002/ejhf.1668. Epub 2019 Nov 14.

Tailoring therapy for ischemic cardiomyopathy: is Laplace's law enough?

Ther Adv Cardiovasc Dis. 2017 Sep;11(9):231-234. doi: 10.1177/1753944717718719. Epub 2017 Jul 10.

Branko Furst's Radical Alternative: Is the Heart Moved by the Blood, Rather Than Vice Versa?

P T. 2017 Jan;42(1):33-39.